Table 2.
Secondary Efficacy Variables (FAS)
| Efficacy variable | FAS (n = 88) |
|---|---|
| CGI‐S | |
| l‐dopa baseline score | 4.26 ± 0.92 |
| APO treatment score | 3.73 ± 0.93 |
| Treatment effect | 0.53 ± 0.92 |
| P value | P < 0.0001 |
| PGI‐S | |
| l‐dopa baseline score | 4.34 ± 0.99 |
| APO treatment score | 3.37 ± 1.30 |
| Treatment effect | 0.98 ± 1.53 |
| P value | P < 0.0001 |
| EQ‐5D visual analogue scale (VAS) | |
| l‐dopa baseline score | 50.38 ± 21.28 |
| APO treatment score | 65.67 ± 20.86 |
| Treatment effect | 15.28 ± 22.11 |
| P value | P < 0.0001 |
| EQ‐5D‐3L index score | |
| l‐dopa baseline score | 3.430 ± 1.51 |
| APO treatment score | 2.18 ± 1.60 |
| Treatment effect | 1.11 ± 1.72 |
| P value | P < 0.0001 |
| Hoehn and Yahr stage | |
| Pre‐APO score (during OFF) | 2.79 ± 0.66 |
| 15 minutes post‐APO (during ON) | 2.31 ± 0.54 |
| Treatment effect | 0.48 ± 0.58 |
| P value | P < 0.0001 |
| UPDRS motor score | |
| Pre‐APO score (during OFF) | 35.53 ± 9.79 |
| 15 minutes post‐APO (during ON) | 17.32 ± 8.81 |
| Treatment effect | 18.22 ± 8.80 |
| P value | P < 0.0001 |
APO, apomorphine; FAS, full analysis set; CGI‐S, Clinical Global Impressions of Severity; PGI‐S, Patient Global Impressions of Severity; UPDRS, Unified Parkinson's Disease Rating Scale.